

In the Claims

1. – 2. (Cancelled)

3. (Withdrawn) The method according to claim 2, wherein the protein substance comprises all or part of the disintegrin domain of metargidin and having an amino-acid sequence of SEQ ID NO. 2 or a derivative thereof.

4. – 12. (Cancelled)

13. (New) A method of inhibiting angiogenesis, tumor invasion, or formation of metastases in a mammal comprising:

administering to the mammal a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.

14. (New) The method according to claim 13, wherein the nucleic acid molecule is inserted into an expression vector.

15. (New) The method according to claim 14, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.

16. (New) The method according to claim 15, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1.

17. (New) A method of treating cancer in a mammal comprising administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID No. 1.

18. (New) The method according to claim 17, wherein the nucleic acid molecule is inserted into an expression vector.

19. (New) The method according to claim 18, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.

20. (New) A method according to claim 19, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1.

21. (New) A method of treating psoriasis in a mammal comprising administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.

22. (New) The method according to claim 21, wherein the nucleic acid molecule is inserted into an expression vector.

23. (New) The method according to claim 22, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1.